Avexa partners for hep C
Thursday, 05 June, 2008
Avexa (ASX: AVX) has announced plans to collaborate with Chinese pharmaceutical company TargetDrug on its hepatitis C virus (HCV) program.
Avexa is a Melbourne-based biotechnology company which is searching for new treatments for HCV. In this second stage of its research, the company will attempt to develop new methods to inhibit HCV replication.
Datamonitor estimates the already lucrative HCV market will grow to $4.4 billion by 2010.
Avexa also announced that the first of its Phase III studies of apricitabine for drug-resistant HIV is progressing well, with the first component of recruitment due to be completed in the third quarter of this year.
Sunscreen and supplements can lower your vitamin D levels
People who use SPF50+ sunscreen daily are more likely to be vitamin D deficient, while taking...
Low-dose drug prevents diabetes progression in young people
A low dose of the immunomodulatory drug anti-thymocyte globulin (ATG) appears safe and effective...
Mediterranean-style diet benefits maternal and infant health
Two studies have found that a Mediterranean-style diet benefits maternal health during pregnancy...
